Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present CV Sciences, Inc. (OTC: CVSI).

Full DD Report for CVSI

You must become a subscriber to view this report.


Recent News from (OTC: CVSI)

Pomerantz Law Firm Announces the Filing of a Class Action against CV Sciences, Inc. and Certain Officers - CVSI
NEW YORK, NY / ACCESSWIRE / September 8, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against CV Sciences, Inc. ("CV Sciences" or the "Company") (OTCQB: CVSI) and certain of its officers. The class action, filed in United States District Court, District of Nevada...
Source: ACCESSWIRE IA
Date: September, 08 2018 08:17
Pawar Law Group Announces a Securities Class Action Lawsuit Against CV Sciences, Inc. - CVSI
NEW YORK, NY / ACCESSWIRE / September 7, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of CV Sciences, Inc. (OTCQB: CVSI) from June 19, 2017 through August 20, 2018, inclusive (the "Class Period"). The lawsuit seeks...
Source: ACCESSWIRE IA
Date: September, 07 2018 23:20
CV SCIENCES LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In CV Sciences, Inc. To Contact The Firm
NEW YORK , Sept. 7, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CV Sciences, Inc. ("CV Sciences" or the "Company") (Other OTC:CVSI) of the October 23, 2018 deadline to seek the role of lead plaintiff in a federal secur...
Source: PR Newswire
Date: September, 07 2018 18:23
Investor Alert: Kaplan Fox Announces Investigation Of CV Sciences, Inc.
NEW YORK , Sept. 6, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of CV Sciences, Inc. ("CV Sciences" or the "Company") (OTC: CVSI).  Investors who purchased CV Sciences common stock between June 19, 20...
Source: PR Newswire
Date: September, 06 2018 10:07
CV Sciences Sales Are Booming, Debt Free and Potential Uplisting in the CBD Sector
NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on CV Sciences, Inc. (OTCQB: CVSI), a company that operates two busine...
Source: ACCESSWIRE IA
Date: September, 06 2018 08:05
CV SCIENCES, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Nevada against CV Sciences, Inc.
NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a federal securities class action lawsuit has been filed in the United States District for the District of Nevada against CV Sciences, Inc. ("CV Sciences" or the "Company") (O...
Source: GlobeNewswire
Date: September, 05 2018 16:05
Robbins Arroyo LLP: CV Sciences, Inc. (CVSI) Misled Shareholders According to a Recently Filed Class Action
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of CV Sciences, Inc. (Other OTC: CVSI) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between June 19, 2017 and August 20...
Source: Business Wire
Date: September, 05 2018 13:38
CV Sciences, Inc. to Present and Exhibit as Gold Sponsor at Natural Products Expo East 2018 in Baltimore, Maryland, September 12-15, 2018
Company enters its 3rd year sponsoring and exhibiting at the nation's second largest natural products trade show, offering natural health retailers show specials, one-on-one education, and a wide selection of product offerings. LAS VEGAS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- CV Sciences...
Source: GlobeNewswire
Date: September, 05 2018 08:45
Lawsuit for Investors in shares of CV Sciences, Inc. (OTC: CVSI) announced by Shareholders Foundation
SAN DIEGO, CA / ACCESSWIRE / September 5, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of CV Sciences, Inc. (OTCQB: CVSI). Investors, who purchased shares of CV Sciences, Inc. (OTC: CVSI), have certain options and for certain in...
Source: ACCESSWIRE IA
Date: September, 05 2018 08:20
Pot stocks perk up premarket
Cannabis stocks are showing some life premarket. Cronos Group (NASDAQ: CRON ) is up  24%  on robust volume, Canopy Growth (NYSE: CGC ) is up  7%  on increased volume and Tilray (NASDAQ: TLRY ) is up  11%  on average volume. More news on: Cronos Group, Inc., Ca...
Source: SeekingAlpha
Date: September, 05 2018 07:50

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-184.6554.774.884.61564,860
2018-12-174.724.684.984.601,013,792
2018-12-144.704.814.904.301,328,179
2018-12-135.564.7155.604.712,785,563
2018-12-125.345.395.585.142,098,609

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-18224,397557,76040.2318Short
2018-12-17365,6091,008,19736.2636Short
2018-12-14532,6801,326,37940.1605Short
2018-12-131,252,0172,765,03245.2804Short
2018-12-12915,2312,077,71544.0499Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CVSI.


About CV Sciences, Inc. (OTC: CVSI)

Logo for CV Sciences, Inc. (OTC: CVSI)

CV Sciences, Inc. is a life science company that operates through two segments, specialty pharmaceuticals and consumer products. The Company focuses on developing and commercializing proprietary prescription drugs utilizing synthetic cannabidiol CBD as the active pharmaceutical ingredient and is engaged in the development, manufacturing, marketing and sale of consumer products containing plant based CBD, which is refined into its own proprietary branded products. CV Sciences initial drug candidate CVSI is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction. The market for cessation of smokeless tobacco use and addiction is estimated at billion, growing to over billion in the next years.

 

Contact Information

 

 

Current Management

  • Michael Mona, Jr. / President, CEO
  • Joseph Dowling / CFO, Secretary
  • Michael Mona, Jr. / Chairman
  • James McNulty / Independent Director, Audit Committee Member, Compensation Committee Member
  • Stephen Schmitz / Independent Director, Compensation Committee Member
  • Gary Sligar / Independent Director, Audit Committee Member

Current Share Structure

  • Market Cap: $37,167,175 - 03/15/2018
  • Authorized: 190,000,000 - 11/07/2017
  • Issue and Outstanding: 90,512,565 - 11/07/2017
  • Float: 20,890,348 - 07/10/2017

 


Recent Filings from (OTC: CVSI)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 24 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 08 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 18 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 14 2017

 

 


Daily Technical Chart for (OTC: CVSI)

Daily Technical Chart for (OTC: CVSI)


Stay tuned for daily updates and more on (OTC: CVSI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CVSI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CVSI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CVSI and does not buy, sell, or trade any shares of CVSI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/